Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01695434 · ClinicalTrials.gov registry record

A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months

A clinical trial of Multiple Sclerosis, sponsored by University at Buffalo.

Completed
Registry status
60
Enrollment target
1
Study location

NCT01695434 is a study of Multiple Sclerosis that has completed, run by University at Buffalo. The registered enrollment target is 60 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01695434, a study of Multiple Sclerosis, has completed, sponsored by University at Buffalo.

COMPLETED
Registry status
60 participants
Enrollment target
1
Study location

Study Summary

To explore whether treatment with glatiramer acetate (GA) may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population of healthy controls.

Conditions Studied

Interventions

  • OTHER MRI

Study Locations (1)

New York

  • Buffalo Neuroimaging Analysis Center - Buffalo

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2012-06
Est. Completion 2013-02

Sponsor

University at Buffalo

67 total trials

What the Registry Record Tells You About NCT01695434

The ClinicalTrials.gov registry entry for NCT01695434 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (90% lower). The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which MRI is the first listed.

NCT01695434 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT01695434 about?

NCT01695434 is a clinical study titled "A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months". To explore whether treatment with glatiramer acetate (GA) may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population of healthy controls.

What is the current status of trial NCT01695434?

This trial is currently completed. The enrollment target is 60 participants. The study started on 2012-06. Estimated completion is 2013-02.

What conditions does trial NCT01695434 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT01695434?

The interventions under investigation include: MRI (OTHER).

Who is sponsoring clinical trial NCT01695434?

This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01695434 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.